Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs

The efficacy of targeted MAPK signalling pathway inhibitors (MAPKi) in metastatic melanoma therapy is limited by the development of resistance mechanisms that results in disease relapse. This situation still requires treatment alternatives for melanoma patients with acquired resistance to targeted t...

Descripción completa

Detalles Bibliográficos
Autores principales: Makino, Elena, Gutmann, Vanessa, Kosnopfel, Corinna, Niessner, Heike, Forschner, Andrea, Garbe, Claus, Sinnberg, Tobias, Schittek, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133963/
https://www.ncbi.nlm.nih.gov/pubmed/30206212
http://dx.doi.org/10.1038/s41419-018-0952-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133963/
https://www.ncbi.nlm.nih.gov/pubmed/30206212
http://dx.doi.org/10.1038/s41419-018-0952-8

Ejemplares similares